Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548472 | 0.98 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4CXCR2ACHE | |
| SCHEMBL502662 | 0.95 | SLC6A3 (0.37) | SLC6A3SLC6A2SLC6A4CXCR2ACHE | |
| SCHEMBL1955758 | 0.85 | LMNA (0.31) | CXCR2 | |
| SCHEMBL8197222 | 0.85 | LMNA (0.31) | CXCR2 | |
| SCHEMBL2482088 | 0.85 | LMNA (0.31) | CXCR2 | |
| SCHEMBL2481485 | 0.85 | LMNA (0.31) | CXCR2 | |
| SCHEMBL6503256 | 0.85 | SLC6A2 (0.36) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL17318442 | 0.84 | ADORA1 (0.37) | MAPTALDH1A1HSD17B10 | |
| SCHEMBL12592486 | 0.84 | ADORA1 (0.37) | MAPTALDH1A1HSD17B10 | |
| SCHEMBL8202859 | 0.84 | ADORA1 (0.37) | MAPTALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115433163-A | NLRP3 inflammasome inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
| EP-3666758-A1 | PROCESS FOR THE PREPARATION OF A SULFONAMIDE DERIVATIVE | AbbVie Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10407382-B2 | EP4 agonists as therapeutic compounds | ALLERGAN, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3152188-B1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2019-02-13 | — | — | EP | disclosed |
| US-10100043-B2 | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180251426-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-09-06 | — | — | US | disclosed |
| US-20180170858-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-9926262-B2 | EP4 agonists as therapeutic compounds | ALLERGAN, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170183293-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2017-06-29 | — | — | US | disclosed |
| EP-3152188-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2017-04-12 | — | — | EP | disclosed |
| US-20100160322-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100152183-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-17 | — | — | US | disclosed |
| US-20090209755-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090209755-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090209755-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| WO-2009091016-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-07-23 | — | — | WO | disclosed |
| EP-1790644-A1 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1448544-B1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | LILLY CO ELI (US) | 2007-05-16 | — | — | EP | disclosed |
| US-7217734-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217734-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100043-B2 | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation | HBB, MB, HBG2 | SLC6A3 3033/4885SLC6A2 3059/4885SLC6A4 2638/4885 |
| US-20180251426-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SLC6A3 4856/4885SLC6A2 4844/4885SLC6A4 4857/4885 |
| US-20100152183-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | SLC6A3 4845/4885SLC6A2 4748/4885SLC6A4 4832/4885 |
| US-20090209755-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | SLC6A3 340/4885SLC6A2 300/4885SLC6A4 1105/4885 |
| US-10407382-B2 | EP4 agonists as therapeutic compounds | PTGER4, PTGER1, PTGER3 | SLC6A3 3757/4885SLC6A2 4260/4885SLC6A4 1435/4885 |
| US-20170183293-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | PTGER4, PTGER1, PTGER3 | SLC6A3 3487/4885SLC6A2 4117/4885SLC6A4 1117/4885 |
| US-20100160322-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SLC6A3 4856/4885SLC6A2 4844/4885SLC6A4 4857/4885 |
| US-20180170858-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | PTGER4, PTGER1, PTGER3 | SLC6A3 3487/4885SLC6A2 4117/4885SLC6A4 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.